Attachment V - Page 1 
Center for Vaccine Development 
University of Maryland 
School of Medicine 
Division of Geographic Medicine 
10 South Pine Street 
Baltimore, MD 21201 
Offices and Laboratories (301) 528-5328 
Director s Office (301) 528-7588 
August 29, 1985 
Dr. Wil 1 iam Gar t land 
Director, Office of Reconbinant 
DMA Activities 
NLAID, NTH 
Bldg. 31, Room 4A52 
Bethesda , MD 20205 
Dear Bill: 
I have read the proposed outline on guidelines for him an somatic gene 
therapy. I consider it excellent, balanced, conservative, and sensitive to 
social issues. My only notable conment relates to item 5 a-d on p.18. I 
believe that the points listed therein should be prerequisites for patients to 
participate in the earliest clinical protocols. In this way the highest 
ethical standards will be followed maximun, while a maximun of scientific 
information is obtained that can be applied toward modification of future 
protocols. 
Sincerely, 
Myron M. Levine, M.D. , D.T.P. H. 
Professor and Director 
Center for Vaccine Development 
fiWL/rr 
[ 355 ] 
